ImmunityBio Stock Decline Analysis Amid Broader Market Trends
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 hours ago
0mins
Should l Buy IBRX?
Source: Benzinga
- Market Reaction: ImmunityBio's stock fell 2.75% to $8.37 in premarket trading on Friday, approaching its 52-week high of $8.94, indicating cautious investor sentiment regarding the company's outlook.
- Distribution Partnership: The company has expanded access to its Anktiva product in the EU through a new distribution agreement with Accord Healthcare, which is expected to enhance its market presence across Europe.
- Technical Analysis: The stock is currently trading 9.2% below its 20-day simple moving average and 12.5% below its 100-day simple moving average, indicating a bearish trend in the short to medium term, suggesting investors should exercise caution.
- Earnings Forecast: ImmunityBio is set to report earnings on March 6, with analysts estimating a loss of 9 cents per share and revenue of $37.51 million, highlighting the company's potential for revenue growth despite current challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.610
Low
5.00
Averages
7.33
High
9.00
Current: 8.610
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Accelerates Global Expansion and Innovation Initiatives
- Global Expansion Initiative: ImmunityBio has partnered with Accord Healthcare to expand access to Anktiva across 30 countries, aiming to enhance its global market share and meet the increasing demand for cancer treatments.
- Regulatory Approval Progress: The company recently received EU approval for Anktiva in combination with BCG for certain bladder cancer patients, marking the therapy's legal use across all EU member states, Norway, Iceland, and Liechtenstein, which is expected to significantly boost sales growth.
- Innovative Manufacturing Vision: Soon-Shiong has proposed the establishment of a 'world bank of natural killer cells,' utilizing AI-driven manufacturing robots to automate the storage and engineering of trillions of natural killer cells at global cancer centers, aiming to provide off-the-shelf therapies for cancer patients.
- Positive Market Reaction: ImmunityBio's stock has risen nearly 1% over the past week and has skyrocketed 225% year-to-date, reflecting strong investor confidence in the company's growth potential, particularly in light of regulatory approvals and market expansion efforts.
See More
ImmunityBio Establishes New Unit in Saudi Arabia
- New Unit Establishment: ImmunityBio has established a new unit in Saudi Arabia to support the distribution and commercialization of Anktiva across the Middle East, which is expected to significantly enhance the company's market penetration in the region.
- Drug Authorization Progress: Earlier this week, the European Commission granted conditional marketing authorization for Anktiva in the treatment of BCG-unresponsive NMIBC CIS, marking a significant step in the drug's global market expansion and anticipated future sales growth.
- Optimistic Analyst Ratings: According to Koyfin data, all five analysts covering IBRX stock rate it as 'Buy' or higher, with a 12-month average price target of $11.80, representing a potential upside of approximately 37% from the stock's last closing price.
- Market Sentiment Shift: On Stocktwits, retail sentiment around IBRX stock rose from 'bullish' to 'extremely bullish' over the past 24 hours, while message volume remained at high levels, reflecting increased investor confidence in the company's future performance.
See More
ImmunityBio Stock Decline Analysis Amid Broader Market Trends
- Market Reaction: ImmunityBio's stock fell 2.75% to $8.37 in premarket trading on Friday, approaching its 52-week high of $8.94, indicating cautious investor sentiment regarding the company's outlook.
- Distribution Partnership: The company has expanded access to its Anktiva product in the EU through a new distribution agreement with Accord Healthcare, which is expected to enhance its market presence across Europe.
- Technical Analysis: The stock is currently trading 9.2% below its 20-day simple moving average and 12.5% below its 100-day simple moving average, indicating a bearish trend in the short to medium term, suggesting investors should exercise caution.
- Earnings Forecast: ImmunityBio is set to report earnings on March 6, with analysts estimating a loss of 9 cents per share and revenue of $37.51 million, highlighting the company's potential for revenue growth despite current challenges.
See More
ImmunityBio Establishes Subsidiary in Saudi Arabia for ANKTIVA Launch
- Subsidiary Established: ImmunityBio has established a wholly owned subsidiary in Saudi Arabia to support physicians and healthcare systems throughout the MENA region, thereby enhancing its market penetration capabilities in this critical area.
- Product Registration Success: The company received a Registration Certificate from the Saudi FDA for ANKTIVA, which is set to begin distribution within the next 60 days, marking its official entry into the Saudi market and addressing the rising demand for cancer treatments.
- Partnership Formation: ImmunityBio has partnered with Biopharma and Cigalah, two of the largest pharmaceutical distributors in the Middle East, to support the commercialization of ANKTIVA in Saudi Arabia and the broader MENA region, which is expected to accelerate patient access to this innovative therapy.
- Regulatory Expansion Discussions: The company has initiated discussions with the Saudi FDA and UAE regulatory authorities to expand ANKTIVA's indications beyond lung and bladder cancers, demonstrating its strategic positioning and long-term growth potential in the regional market.
See More
U.S. Stock Futures Rise as Investors Eye Economic Data
- Economic Data Focus: Investors are closely monitoring the upcoming release of the PCE index and fourth-quarter GDP data, which will influence market expectations for Federal Reserve rate cuts and potentially alter investor risk appetite.
- Futures Market Dynamics: As of 3:00 a.m. ET on Friday, Nasdaq and S&P 500 futures rose by 0.2%, while Dow and Russell 2000 futures increased by 0.1%, indicating a positive sentiment in the market ahead of key economic data.
- Tech Stock Movements: Nvidia is reportedly finalizing a $30 billion equity investment in OpenAI, replacing an earlier $100 billion deal, highlighting ongoing interest and investment in the artificial intelligence sector.
- Market Sentiment Shifts: Retail sentiment towards the SPDR S&P 500 ETF remains 'neutral', while the Invesco QQQ Trust ETF has shifted from 'neutral' to 'bearish', reflecting a cautious outlook on tech stocks.
See More
Pomerantz LLP Investigates ImmunityBio for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ImmunityBio and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors and highlight potential risks in corporate governance and compliance.
- Clinical Trial Results Update: On January 23, 2026, ImmunityBio announced that the median overall survival for its chemotherapy-free immunotherapy regimen for recurrent or progressive glioblastoma has not yet been reached, indicating that key clinical trial endpoints have not met expectations, potentially impacting investor confidence.
- Stock Price Decline Impact: Following the clinical results announcement, ImmunityBio's stock price fell by $0.89, a decline of 12.13%, closing at $6.45 per share, reflecting market concerns about the company's future prospects and possibly leading to further investor sell-offs.
- Law Firm Background: Pomerantz LLP is a premier law firm with over 85 years of experience in corporate, securities, and antitrust class litigation, dedicated to fighting for the rights of victims of securities fraud, demonstrating its expertise and capability in handling such cases.
See More
ImmunityBio Accelerates Global Expansion and Innovation Initiatives
- Global Expansion Initiative: ImmunityBio has partnered with Accord Healthcare to expand access to Anktiva across 30 countries, aiming to enhance its global market share and meet the increasing demand for cancer treatments.
- Regulatory Approval Progress: The company recently received EU approval for Anktiva in combination with BCG for certain bladder cancer patients, marking the therapy's legal use across all EU member states, Norway, Iceland, and Liechtenstein, which is expected to significantly boost sales growth.
- Innovative Manufacturing Vision: Soon-Shiong has proposed the establishment of a 'world bank of natural killer cells,' utilizing AI-driven manufacturing robots to automate the storage and engineering of trillions of natural killer cells at global cancer centers, aiming to provide off-the-shelf therapies for cancer patients.
- Positive Market Reaction: ImmunityBio's stock has risen nearly 1% over the past week and has skyrocketed 225% year-to-date, reflecting strong investor confidence in the company's growth potential, particularly in light of regulatory approvals and market expansion efforts.
See More
ImmunityBio Establishes New Unit in Saudi Arabia
- New Unit Establishment: ImmunityBio has established a new unit in Saudi Arabia to support the distribution and commercialization of Anktiva across the Middle East, which is expected to significantly enhance the company's market penetration in the region.
- Drug Authorization Progress: Earlier this week, the European Commission granted conditional marketing authorization for Anktiva in the treatment of BCG-unresponsive NMIBC CIS, marking a significant step in the drug's global market expansion and anticipated future sales growth.
- Optimistic Analyst Ratings: According to Koyfin data, all five analysts covering IBRX stock rate it as 'Buy' or higher, with a 12-month average price target of $11.80, representing a potential upside of approximately 37% from the stock's last closing price.
- Market Sentiment Shift: On Stocktwits, retail sentiment around IBRX stock rose from 'bullish' to 'extremely bullish' over the past 24 hours, while message volume remained at high levels, reflecting increased investor confidence in the company's future performance.
See More
ImmunityBio Stock Decline Analysis Amid Broader Market Trends
- Market Reaction: ImmunityBio's stock fell 2.75% to $8.37 in premarket trading on Friday, approaching its 52-week high of $8.94, indicating cautious investor sentiment regarding the company's outlook.
- Distribution Partnership: The company has expanded access to its Anktiva product in the EU through a new distribution agreement with Accord Healthcare, which is expected to enhance its market presence across Europe.
- Technical Analysis: The stock is currently trading 9.2% below its 20-day simple moving average and 12.5% below its 100-day simple moving average, indicating a bearish trend in the short to medium term, suggesting investors should exercise caution.
- Earnings Forecast: ImmunityBio is set to report earnings on March 6, with analysts estimating a loss of 9 cents per share and revenue of $37.51 million, highlighting the company's potential for revenue growth despite current challenges.
See More
ImmunityBio Establishes Subsidiary in Saudi Arabia for ANKTIVA Launch
- Subsidiary Established: ImmunityBio has established a wholly owned subsidiary in Saudi Arabia to support physicians and healthcare systems throughout the MENA region, thereby enhancing its market penetration capabilities in this critical area.
- Product Registration Success: The company received a Registration Certificate from the Saudi FDA for ANKTIVA, which is set to begin distribution within the next 60 days, marking its official entry into the Saudi market and addressing the rising demand for cancer treatments.
- Partnership Formation: ImmunityBio has partnered with Biopharma and Cigalah, two of the largest pharmaceutical distributors in the Middle East, to support the commercialization of ANKTIVA in Saudi Arabia and the broader MENA region, which is expected to accelerate patient access to this innovative therapy.
- Regulatory Expansion Discussions: The company has initiated discussions with the Saudi FDA and UAE regulatory authorities to expand ANKTIVA's indications beyond lung and bladder cancers, demonstrating its strategic positioning and long-term growth potential in the regional market.
See More
U.S. Stock Futures Rise as Investors Eye Economic Data
- Economic Data Focus: Investors are closely monitoring the upcoming release of the PCE index and fourth-quarter GDP data, which will influence market expectations for Federal Reserve rate cuts and potentially alter investor risk appetite.
- Futures Market Dynamics: As of 3:00 a.m. ET on Friday, Nasdaq and S&P 500 futures rose by 0.2%, while Dow and Russell 2000 futures increased by 0.1%, indicating a positive sentiment in the market ahead of key economic data.
- Tech Stock Movements: Nvidia is reportedly finalizing a $30 billion equity investment in OpenAI, replacing an earlier $100 billion deal, highlighting ongoing interest and investment in the artificial intelligence sector.
- Market Sentiment Shifts: Retail sentiment towards the SPDR S&P 500 ETF remains 'neutral', while the Invesco QQQ Trust ETF has shifted from 'neutral' to 'bearish', reflecting a cautious outlook on tech stocks.
See More
Pomerantz LLP Investigates ImmunityBio for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ImmunityBio and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors and highlight potential risks in corporate governance and compliance.
- Clinical Trial Results Update: On January 23, 2026, ImmunityBio announced that the median overall survival for its chemotherapy-free immunotherapy regimen for recurrent or progressive glioblastoma has not yet been reached, indicating that key clinical trial endpoints have not met expectations, potentially impacting investor confidence.
- Stock Price Decline Impact: Following the clinical results announcement, ImmunityBio's stock price fell by $0.89, a decline of 12.13%, closing at $6.45 per share, reflecting market concerns about the company's future prospects and possibly leading to further investor sell-offs.
- Law Firm Background: Pomerantz LLP is a premier law firm with over 85 years of experience in corporate, securities, and antitrust class litigation, dedicated to fighting for the rights of victims of securities fraud, demonstrating its expertise and capability in handling such cases.
See More
